Zajac-Spychala Olga, Kampmeier Stefanie, Lehrnbecher Thomas, Groll Andreas H
Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznań, Poland.
Institute of Hygiene, University Hospital Münster, Münster, Germany.
Front Pediatr. 2022 Feb 10;9:782530. doi: 10.3389/fped.2021.782530. eCollection 2021.
Haematopoietic stem cell transplantation (HSCT) in paediatric patients with acute lymphoblastic leukaemia (ALL) is associated with a variety of infectious complications which result in significant morbidity and mortality. These patients are profoundly immunocompromised, and immune reconstitution after HSCT generally occurs in astrictly defined order. During the early phase after HSCT until engraftment, patients are at risk of infections due to presence of neutropenia and mucosal damage, with Gramme-positive and Gramme-negative bacteria and fungi being the predominant pathogens. After neutrophil recovery, the profound impairment of cell-mediated immunity and use of glucocorticosteroids for control of graft-vs.-host disease (GvHD) increases the risk of invasive mould infection and infection or reactivation of various viruses, such as cytomegalovirus, varicella zoster virus, Epstein-Barr virus and human adenovirus. In the late phase, characterised by impaired cellular and humoral immunity, particularly in conjunction with chronic GvHD, invasive infections with encapsulated bacterial infections are observed in addition to fungal and viral infections. HSCT also causes a loss of pretransplant naturally acquired and vaccine-acquired immunity; therefore, complete reimmunization is necessary to maintain long-term health in these patients. During the last two decades, major advances have been made in our understanding of and in the control of infectious complications associated with HSCT. In this article, we review current recommendations for the diagnosis, prophylaxis and treatment of infectious complications following HSCT for ALL in childhood.
小儿急性淋巴细胞白血病(ALL)患者进行造血干细胞移植(HSCT)会伴有多种感染并发症,这些并发症会导致显著的发病率和死亡率。这些患者存在严重的免疫功能低下,HSCT后的免疫重建通常按严格定义的顺序发生。在HSCT后直至植入的早期阶段,由于存在中性粒细胞减少和黏膜损伤,患者有感染风险,革兰氏阳性菌、革兰氏阴性菌和真菌是主要病原体。中性粒细胞恢复后,细胞介导免疫的严重受损以及使用糖皮质激素控制移植物抗宿主病(GvHD)会增加侵袭性霉菌感染以及各种病毒(如巨细胞病毒、水痘带状疱疹病毒、爱泼斯坦-巴尔病毒和人腺病毒)感染或再激活的风险。在后期,以细胞免疫和体液免疫受损为特征,特别是与慢性GvHD相关时,除了真菌和病毒感染外,还会观察到包膜细菌感染引起的侵袭性感染。HSCT还会导致移植前自然获得的和疫苗获得的免疫力丧失;因此,为了维持这些患者的长期健康,完全重新免疫是必要的。在过去二十年中,我们对与HSCT相关的感染并发症的认识和控制取得了重大进展。在本文中,我们综述了目前关于儿童ALL患者HSCT后感染并发症的诊断、预防和治疗的建议。